Stock Track | DaVita HealthCare Partners Soars 17.18% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Profit Forecast

Stock Track02-03 22:47

DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for 2026 that exceeded analyst estimates.

The kidney care provider reported adjusted earnings per share of $3.40 for the fourth quarter, surpassing analyst expectations. Revenue for the quarter rose to $3.62 billion, also beating estimates. The company attributed the strong performance to steady demand for its kidney dialysis services and higher reimbursement rates.

Looking ahead, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the average analyst estimate, signaling strong confidence in future performance. Additionally, the company announced a strategic minority investment in home-care provider Elara Caring to co-develop a kidney-specific home-based care model, which is expected to support growth initiatives in personalized patient care.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193598597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193598597","market":"nz","top_or_hot":-1,"title":"Stock Track | DaVita HealthCare Partners Soars 17.18% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Profit Forecast","media":"Stock Track","content":"<p>DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for 2026 that exceeded analyst estimates.</p><p>The kidney care provider reported adjusted earnings per share of $3.40 for the fourth quarter, surpassing analyst expectations. Revenue for the quarter rose to $3.62 billion, also beating estimates. The company attributed the strong performance to steady demand for its kidney dialysis services and higher reimbursement rates.</p><p>Looking ahead, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the average analyst estimate, signaling strong confidence in future performance. Additionally, the company announced a strategic minority investment in home-care provider Elara Caring to co-develop a kidney-specific home-based care model, which is expected to support growth initiatives in personalized patient care.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DaVita HealthCare Partners Soars 17.18% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Profit Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DaVita HealthCare Partners Soars 17.18% in Pre-Market on Strong Q4 Earnings Beat and Upbeat 2026 Profit Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-03 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for 2026 that exceeded analyst estimates.</p><p>The kidney care provider reported adjusted earnings per share of $3.40 for the fourth quarter, surpassing analyst expectations. Revenue for the quarter rose to $3.62 billion, also beating estimates. The company attributed the strong performance to steady demand for its kidney dialysis services and higher reimbursement rates.</p><p>Looking ahead, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the average analyst estimate, signaling strong confidence in future performance. Additionally, the company announced a strategic minority investment in home-care provider Elara Caring to co-develop a kidney-specific home-based care model, which is expected to support growth initiatives in personalized patient care.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVA","symbol_name":"达维塔保健","start_time":0,"source_url":"","article_id":"1193598597","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193598597","pubTimestamp":1770130046,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVA":"达维塔保健"},"translate_title":"股票追踪|DaVita HealthCare Partners盘前飙升17.18%，第四季度盈利强劲，2026年盈利预测乐观","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":1},"content_text":"DaVita HealthCare Partners' stock soared 17.18% in pre-market trading on Tuesday, driven by the company's better-than-expected fourth-quarter financial results and an optimistic profit forecast for 2026 that exceeded analyst estimates.The kidney care provider reported adjusted earnings per share of $3.40 for the fourth quarter, surpassing analyst expectations. Revenue for the quarter rose to $3.62 billion, also beating estimates. The company attributed the strong performance to steady demand for its kidney dialysis services and higher reimbursement rates.Looking ahead, DaVita provided 2026 adjusted EPS guidance in the range of $13.60 to $15.00, significantly above the average analyst estimate, signaling strong confidence in future performance. Additionally, the company announced a strategic minority investment in home-care provider Elara Caring to co-develop a kidney-specific home-based care model, which is expected to support growth initiatives in personalized patient care.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193598597","isCrawlerRequest":true}